United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a new inhalation device, called the TD-300/A, for use with Tyvaso® (treprostinil) Inhalation Solution (Tyvaso).
SUBSCRIBE
Biohealth Innovation
Founding Member of
